Chemotherapy for treatment of AML

In this proposed study, the team will utilize, and add to, data in the West Virginia Cancer Genomics Network in order to identify genetic mutations in AML specific to the West Virginia population. We will compare those mutations to The Cancer Genome Atlas to identify any that are specifically overrepresented in this population, and find mutations that correlate to durability of response.

Subsequently, team members will perform ex-vivo testing of primary patient specimens under four classes of therapy, and identify mutations in those specimens that are candidates for predicting outcome of each class of treatment. These candidate predictive mutations will provide preliminary data for a larger study that will aim to identify a genetic specimen profile for personalizing clinical treatment of AML.